Tried Multiple Migraine Treatments Without Relief? Atogepant May Help
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Tried Multiple Migraine Treatments Without Relief? Atogepant May Help
-
Narrated by:
-
By:
About this listen
A new real-world study shows atogepant (sold under brand name Qulipta) may quickly reduce migraine days—even for those who haven't responded to other treatments. Molly O'Brien has more in this Migraine Minute News Update!
Read more: http://bit.ly/3UcEuJN
CC License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Script:
The GIANT study, published inThe Journal of Headache and Pain, offers real-world evidence that atogepant is a safe, well-tolerated, and effective for migraine prevention—among those whose prior treatments didn't work.
Researchers looked at the impact of 60 mg of atogepant, taken once daily in people with either high-frequency episodic or chronic migraine. Many of the participants had already tried at least three other preventive treatments… including CGRP monoclonal antibodies.
Results? At 12 weeks, on average, participants saw a decrease of 6 migraine days and 11 headache days per month. In fact, nearly 60% of experienced at least a 50 percent drop in migraine days. Pain intensity, disability, and use of acute drugs also dropped.
Some saw improvement in migraine frequency within the first week.